Clinical Trials Browser

Phase 1/2 × contrast agent BR1 × 90 days × Clear all

NCT06329570 2026-04-09

Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)

Phase 1/2 Recruiting

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Neoplasms, Nerve Tissue